Article

Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabine

2024-05-14

Abstract excerpt

<title>Abstract</title> <p>The combination of gemcitabine with platinum agents is a widely used chemotherapy regimen for a number of tumour types. Gemcitabine plus cisplatin remains the current therapeutic choice for biliary tract cancer. Gemcitabine is associated with multiple cellular drug resistance mechanisms and other limitations and has therefore declined in use. NUC-1031 is a phosphorylated form of gemcita...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 58880abc-ddfb-5bac-b5ed-f073bfba45fc
DOI: 10.21203/rs.3.rs-4344105/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabineDOI 10.21203/rs.3.rs-4344105/v1Read

Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancerSemantic proximity Read

Review of the Fluoropyrimidine Antidote Uridine TriacetateSemantic proximity Read

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity Read

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Semantic proximity Read

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms.Semantic proximity Read

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity Read

A Phase I trial to evaluate cisplatin, gemcitabine and the mTOR inhibitor temsirolimus for first-line treatment of participants with transitional cell urothelial cancer, or advanced solid cancerSemantic proximity Read

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.Semantic proximity Read

Gemcitabine and Synthesized Silver Nanoparticles Impact on Chemically Induced Hepatocellular Carcinoma in Male RatsSemantic proximity Read

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.Semantic proximity Read

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatinSemantic proximity Read